These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 31841646)

  • 41. Methylphenidate dosing: twice daily versus three times daily.
    Stein MA; Blondis TA; Schnitzler ER; O'Brien T; Fishkin J; Blackwell B; Szumowski E; Roizen NJ
    Pediatrics; 1996 Oct; 98(4 Pt 1):748-56. PubMed ID: 8885956
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Osmotic Release Oral System Methylphenidate Versus Atomoxetine for the Treatment of Attention-Deficit/Hyperactivity Disorder in Chinese Youth: 8-Week Comparative Efficacy and 1-Year Follow-Up.
    Su Y; Yang L; Stein MA; Cao Q; Wang Y
    J Child Adolesc Psychopharmacol; 2016 May; 26(4):362-71. PubMed ID: 26779845
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of osmotic-controlled release oral delivery system methylphenidate HCl in adults with attention-deficit/hyperactivity disorder in Japan.
    Takahashi N; Koh T; Tominaga Y; Saito Y; Kashimoto Y; Matsumura T
    World J Biol Psychiatry; 2014 Aug; 15(6):488-98. PubMed ID: 24456065
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Sluggish Cognitive Tempo as a Possible Predictor of Methylphenidate Response in Children With ADHD: A Randomized Controlled Trial.
    Froehlich TE; Becker SP; Nick TG; Brinkman WB; Stein MA; Peugh J; Epstein JN
    J Clin Psychiatry; 2018; 79(2):. PubMed ID: 29489078
    [TBL] [Abstract][Full Text] [Related]  

  • 45. An open-label, randomized, active-controlled equivalent trial of osmotic release oral system methylphenidate in children with attention-deficit/hyperactivity disorder in Taiwan.
    Gau SS; Shen HY; Soong WT; Gau CS
    J Child Adolesc Psychopharmacol; 2006 Aug; 16(4):441-55. PubMed ID: 16958569
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Short-term side effects of stimulant medication are increased in preschool children with attention-deficit/hyperactivity disorder: a double-blind placebo-controlled study.
    Firestone P; Musten LM; Pisterman S; Mercer J; Bennett S
    J Child Adolesc Psychopharmacol; 1998; 8(1):13-25. PubMed ID: 9639076
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effect of OROS methylphenidate on encopresis in children with attention-deficit/hyperactivity disorder.
    Yılmaz S; Bilgiç A; Hergüner S
    J Child Adolesc Psychopharmacol; 2014 Apr; 24(3):158-60. PubMed ID: 24168715
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Better efficacy for the osmotic release oral system methylphenidate among poor adherents to immediate-release methylphenidate in the three ADHD subtypes.
    Chou WJ; Chou MC; Tzang RF; Hsu YC; Gau SS; Chen SJ; Wu YY; Huang YF; Liang HY; Cheng H
    Psychiatry Clin Neurosci; 2009 Apr; 63(2):167-75. PubMed ID: 19335386
    [TBL] [Abstract][Full Text] [Related]  

  • 49. OROS methylphenidate in the treatment of adults with ADHD: a 6-month, open-label, follow-up study.
    Marchant BK; Reimherr FW; Halls C; Williams ED; Strong RE
    Ann Clin Psychiatry; 2010 Aug; 22(3):196-204. PubMed ID: 20680193
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Methylphenidate versus dexamphetamine in children with attention deficit hyperactivity disorder: A double-blind, crossover trial.
    Efron D; Jarman F; Barker M
    Pediatrics; 1997 Dec; 100(6):E6. PubMed ID: 9382907
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Weekend holidays during methylphenidate use in ADHD children: a randomized clinical trial.
    Martins S; Tramontina S; Polanczyk G; Eizirik M; Swanson JM; Rohde LA
    J Child Adolesc Psychopharmacol; 2004; 14(2):195-206. PubMed ID: 15319017
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Oppositional defiant disorder in adults with ADHD.
    Reimherr FW; Marchant BK; Olsen JL; Wender PH; Robison RJ
    J Atten Disord; 2013 Feb; 17(2):102-13. PubMed ID: 22100691
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Attention-Deficit/Hyperactivity Disorder and methylphenidate: a dose-response analysis and parent-child comparison of somatic complaints.
    Rapport MD; Randall R; Moffitt C
    J Atten Disord; 2002 Jun; 6(1):15-24. PubMed ID: 12045757
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Changes in Sleep Problems Across Attention-Deficit/Hyperactivity Disorder Treatment: Findings from the Multimodal Treatment of Attention-Deficit/Hyperactivity Disorder Study.
    Ricketts EJ; Sturm A; McMakin DL; McGuire JF; Tan PZ; Smalberg FB; McCracken JT; Colwell CS; Piacentini J
    J Child Adolesc Psychopharmacol; 2018 Dec; 28(10):690-698. PubMed ID: 30388029
    [No Abstract]   [Full Text] [Related]  

  • 55. Efficacy and Safety of HLD200, Delayed-Release and Extended-Release Methylphenidate, in Children with Attention-Deficit/Hyperactivity Disorder.
    Pliszka SR; Wilens TE; Bostrom S; Arnold VK; Marraffino A; Cutler AJ; López FA; DeSousa NJ; Sallee FR; Incledon B; Newcorn JH
    J Child Adolesc Psychopharmacol; 2017 Aug; 27(6):474-482. PubMed ID: 29172680
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A double-blind, placebo-controlled trial of dexmethylphenidate hydrochloride and d,l-threo-methylphenidate hydrochloride in children with attention-deficit/hyperactivity disorder.
    Wigal S; Swanson JM; Feifel D; Sangal RB; Elia J; Casat CD; Zeldis JB; Conners CK
    J Am Acad Child Adolesc Psychiatry; 2004 Nov; 43(11):1406-14. PubMed ID: 15502600
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Efficacy of two long-acting methylphenidate formulations in children with attention- deficit/hyperactivity disorder in a laboratory classroom setting.
    Silva R; Muniz R; Pestreich LK; Brams M; Childress A; Lopez FA
    J Child Adolesc Psychopharmacol; 2005 Aug; 15(4):637-54. PubMed ID: 16190795
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Switching from methylphenidate immediate release to MPH-SODAS in attention-deficit/hyperactivity disorder.
    Maia CR; Matte BC; Ludwig HT; Rohde LA
    Eur Child Adolesc Psychiatry; 2008 Apr; 17(3):133-42. PubMed ID: 17846812
    [TBL] [Abstract][Full Text] [Related]  

  • 59. European, randomized, phase 3 study of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder.
    Coghill D; Banaschewski T; Lecendreux M; Soutullo C; Johnson M; Zuddas A; Anderson C; Civil R; Higgins N; Lyne A; Squires L
    Eur Neuropsychopharmacol; 2013 Oct; 23(10):1208-18. PubMed ID: 23332456
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Long-term medication for ADHD (LMA) trial: 2-year prospective observational study in children and adolescents. Core symptoms, daily functioning, and comorbidity outcomes.
    Johnson M; Johnels JÅ; Östlund S; Jakobsson K; Högstedt J; Larsson PJ; Gillberg C; Billstedt E
    Eur Arch Psychiatry Clin Neurosci; 2024 Jun; 274(4):879-890. PubMed ID: 38280948
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.